NEWS

COVID-19 Update

Safeguarding our people and communities remains our top priority.

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains¹.